<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01269229</url>
  </required_header>
  <id_info>
    <org_study_id>4-2009-0522</org_study_id>
    <nct_id>NCT01269229</nct_id>
  </id_info>
  <brief_title>A Trial of Neoadjuvant FOLFOX6 With Short Course Radiotherapy in Patients With Unresectable Rectal Cancer and Liver Metastasis</brief_title>
  <official_title>A Phase 2 Trial of Neoadjuvant FOLFOX6 With Short Course Radiotherapy in Patients With Unresectable Rectal Cancer and Liver Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is the increase of resection rate of primary cancer in rectal after&#xD;
      short course radiotherapy without interrupt chemotherapy schedule during the period of&#xD;
      chemotherapy. The subject should have the pathologically confirmed for unresectable&#xD;
      (impossible to try Total mesorectal excision) rectal cancer with liver metastasis.&#xD;
&#xD;
      This trial contributes to save the time for decreasing primary tumor in rectal and metastasis&#xD;
      cancer to whole body after short course radiotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete resection (R0) rate for rectal and liver lesions.</measure>
    <time_frame>after surgical resection</time_frame>
    <description>Complete resection (R0 resection) is defined as no residual cancer cells in the resection margn both primary recal mass and liver metastases after simultaneous surgical resection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate (RECIST V1.0)</measure>
    <time_frame>every 4 cycles</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>participants will be followed until death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival time</measure>
    <time_frame>participants will be followed until disease progression or death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity profile</measure>
    <time_frame>participants will be followed until disease progression or death</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">32</enrollment>
  <condition>Rectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>folfox</intervention_name>
    <description>FOLFOX: Day1- Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, 5-FU 400mg/m2 IV bolus -&gt; 2400mg/m2 46hrs continuous</description>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>short course Radiotherapy</intervention_name>
    <description>After FOLFOX 4cycle, subject have short course RTx 5Gy at once this should be continuing for 5days so that subject should have 25Gy within 5days. Then, subjects have another 4 cycle of FOLFOX and evaluate cancer for resection.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject whom should have the pathologically confirmed for unresectable (impossible to&#xD;
             try Total mesorectal excision) rectal cancer with liver metastasis.&#xD;
&#xD;
          -  Over 18 years&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
          -  Proper organ function (hepatic transaminases : &lt; ULN ⅹ5, Bilirubin: &lt; ULNⅹ2,&#xD;
             creatinine (serum): &lt; ULNⅹ 1.5, PLT &gt; 100,000Ul, ANC &gt; 1,500/Ul&#xD;
&#xD;
          -  more than one target lesion (standard by RECIST 1.0)&#xD;
&#xD;
          -  Who should sign on the Informed consent form before participate the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Metastasis in other organ except liver (No matter whether have resection or not)&#xD;
&#xD;
          -  Chronic active hepatitis or cirrhosis&#xD;
&#xD;
          -  History of treatment for colorectal cancer&#xD;
&#xD;
          -  Subject pregnant or breast feeding&#xD;
&#xD;
          -  Uncontrolled disease (eg. infection, hypertension, heart failure, Myocardial&#xD;
             Infarction within 6months)&#xD;
&#xD;
          -  Have been used FOLFOX as an adjuvant therapy&#xD;
&#xD;
          -  Have had adjuvant therapy within 6months&#xD;
&#xD;
          -  Uncontrolled peripheral nerve infection&#xD;
&#xD;
          -  Alcoholic or drug addict&#xD;
&#xD;
          -  Subject currently is enrolled in or ≤30 days from ending other clinical trial.&#xD;
&#xD;
          -  History of other type of cancer except resolved from skin cancer and cervical cancer.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>January 3, 2011</study_first_submitted>
  <study_first_submitted_qc>January 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2011</study_first_posted>
  <last_update_submitted>September 5, 2016</last_update_submitted>
  <last_update_submitted_qc>September 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

